Company / EPS (Diluted)
Avalo Therapeutics, Inc. EPS (Diluted) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$20.91
FY2025
5-year range
-$1063.00 / -$4.43
FY2021-FY2025
Trend
+81.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-1063.00 to $-20.91 over the past 2 years.
Based on SEC 10-K filings.
-20.91 in FY2025.
Improved from $-1063.00 to $-20.91 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 81.6% year-over-year.
- Peak eps (diluted) was recorded in FY2018.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$20.91 | +81.6% |
| FY2024 | -$113.58 | +89.3% |
| FY2023 | -$1063.00 | -23895.5% |
| FY2022 | -$4.43 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | -$1.20 | -385.7% |
| FY2018 | $0.42 | +108.9% |
| FY2017 | -$4.71 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026